What is tesamorelin and where did it come from?

Tesamorelin is a synthetic peptide analog of growth-hormone-releasing hormone (GHRH). It's essentially the natural human GHRH sequence with a chemical modification added to make it more stable and longer-lasting. Researchers study it because it stimulates the body's own growth-hormone release instead of adding hormone from outside.

What has research shown about tesamorelin?

In clinical studies, tesamorelin reduced visceral adipose tissue — the deep fat around internal organs — by roughly 15% versus placebo, while leaving subcutaneous fat and lean mass largely intact. It also raised IGF-1, a marker of increased growth-hormone activity. These findings come from human trials in specific populations and are the reason it remains an active subject in metabolic and body-composition research.

Is tesamorelin FDA approved?

Yes — tesamorelin is approved under the brand name Egrifta for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. That approval applies to the prescription pharmaceutical product only. The research-grade material sold here is for in-vitro and laboratory research use only, not for human or veterinary use.

How does tesamorelin differ from other GH secretagogues like sermorelin?

Both are GHRH analogs that prompt the pituitary to release growth hormone, but tesamorelin carries a stabilizing modification that extends its half-life and durability compared with sermorelin. In research settings it's the analog most associated with clinical data on visceral fat reduction. That track record makes it a common reference point when comparing GHRH-based approaches.

What is the molecular structure of tesamorelin?

Tesamorelin has the molecular formula C221H366N72O67S and a molecular weight of 5135.86 g/mol (CAS 218949-48-5). It's a 44-amino-acid peptide based on human GHRH, with a trans-3-hexenoyl group attached at the N-terminus — the key structural feature that improves its stability.

Tesamorelin

Cut visceral belly fat by 15% in trials

99.92% pure on this exact lot, verified by an independent lab, not by us
Tested in America. Ships within 1 business day, stored frozen, stable at room temperature until you mix it
Retest it at any lab. If it doesn't match our report, every dollar back

$119/ 10mg vial

$59.50 per vial with Buy 1, Get 1 Free

Buy 1, Get 1 Free — add 2 to cart, applied automatically

In stock

99.92% pure on this exact lot, verified by an independent lab, not by us
Tested in America. Ships within 1 business day, stored frozen, stable at room temperature until you mix it
Retest it at any lab. If it doesn't match our report, every dollar back

VISAAMEXPayPal

Secure checkout

All products currently listed on this site are for research purposes only.

Frequently bought together

Related laboratory supplies.

Reconstitution Solution · 3ml

Essential

GHK-Cu · 50mg

Melanotan II · 10mg

Add all (3)$97

Certificate of analysis

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity
Raw chromatogram + mass confirmation attached
Signed off by the lab's Principal Chemist
Permanent archive — searchable by lot ID

or browse the lot archive

Tesamorelin · 10mgLot ERWAU3Live

Purity by HPLC-UV

99.92%

Tested by: Freedom Diagnostics
Tested on: 12 Oct 2026
Net content: 8.87 mg

Contaminant screens

Heavy metalsEndotoxinsMicrobialSolvents

See all lab reports

Live batch data

Freedom Diagnostics

Independent analytical lab

Certificate of Analysis

RESULT · PASS

Lot ERWAU3Verified

Tesamorelin 10mg

HPLC purity

99.92%

Pass · Meets spec

Tested

12 Oct 2026

HPLC-UV + LC-MS

Analytical results

Identity (LC-MS)ConfirmedPASS

Net content8.87 mgPASS

HPLC Chromatogram

Main peak 99.92% · other 0.08%

Alex JohnsonPrincipal Chemist

Authentichain · Verified 79×

GHRH signalreceptor agonist

IGF-1 axisdownstream mediator

Lipolysisvisceral fat

How Tesamorelin works

Tesamorelin is studied to work upstream of growth hormone — it triggers the body's own signalling rather than replacing the hormone directly.

GHRH signalreceptor agonist

It binds the GHRH receptor in the pituitary, prompting the gland to release growth hormone in natural pulses.

IGF-1 axisdownstream mediator

The extra growth hormone drives the liver to make more IGF-1, the messenger behind many of growth hormone's metabolic effects.

Lipolysisvisceral fat

Higher growth-hormone activity is studied for how it encourages breakdown of deep visceral fat stores while sparing lean tissue.

For research use only. Mechanisms described reflect published preclinical and clinical literature.

Every batch we've tested

Anyone can show you one good report. Here is every batch of Tesamorelin we have ever released, newest first, each with its own signed report. Nothing hidden, nothing cherry-picked.

9 batches on record · latest tested 12 Oct 2026

All lab reportsEvery Tesamorelin batch, on one page.The full testing history with every signed report. No login, no email wall.See all lab reports

What the studies found

Published findings on this compound, each linked to its source. Animal and lab results are context, not claims about this product.

Visceral fatClinical

−15.2%

In a 26-week trial of 412 adults with HIV and excess belly fat, tesamorelin cut deep visceral fat by 15.2%, while it rose 5.0% on placebo.

vs +5.0% on placebo

NEJM 2007 · phase 3 RCT, n=412

Placebo+5.0%

Tesamorelin−15.2%

Change in visceral fat on CT scan at 26 weeks

Liver fatClinical

35%

In a 12-month trial of 61 adults with HIV and fatty liver, tesamorelin cut liver fat by 37%, and 35% reached a normal level, versus 4% on placebo.

vs 4% on placebo

35%

Reached normal liver fat

Share under 5% liver fat at 12 months, vs 4% placebo

Lancet HIV 2019 · RCT, n=61

Liver scarringClinical

10.5%

In a 12-month trial of 61 adults with HIV and fatty liver, liver scarring worsened on biopsy in 10.5% of those on tesamorelin versus 37.5% on placebo.

vs 37.5% on placebo

Placebo37.5%

Tesamorelin10.5%

Share whose liver fibrosis stage worsened over 12 months

Lancet HIV 2019 · RCT, n=61